PT  - JOURNAL ARTICLE
AU  - Wenjuan Su
AU  - Oladapo Yeku
AU  - Srinivas Olepu
AU  - Alyssa Genna
AU  - Jae-Sook Park
AU  - Hongmei Ren
AU  - Guangwei Du
AU  - Michael H. Gelb
AU  - Andrew J. Morris
AU  - Michael A. Frohman
TI  - 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a Phospholipase D Pharmacological Inhibitor That Alters Cell Spreading and Inhibits Chemotaxis
AID  - 10.1124/mol.108.053298
DP  - 2009 Mar 01
TA  - Molecular Pharmacology
PG  - 437--446
VI  - 75
IP  - 3
4099  - http://molpharm.aspetjournals.org/content/75/3/437.short
4100  - http://molpharm.aspetjournals.org/content/75/3/437.full
SO  - Mol Pharmacol2009 Mar 01; 75
AB  - The signaling enzyme phospholipase D (PLD) and the lipid second messenger it generates, phosphatidic acid (PA), are implicated in many cell biological processes, including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. PLD production of PA is inhibited by the primary alcohol 1-butanol, which has thus been widely employed to identify PLD/PA-driven processes. However, 1-butanol does not always effectively reduce PA accumulation, and its use may result in PLD-independent deleterious effects. Consequently, identification of potent specific small-molecule PLD inhibitors would be an important advance for the field. We examine one such here, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI), which was identified recently in an in vitro chemical screen for PLD2 inhibitors, and show that it rapidly blocks in vivo PA production with subnanomolar potency. We were surprised to find that several biological processes blocked by 1-butanol are not affected by FIPI, suggesting the need for re-evaluation of proposed roles for PLD. However, FIPI does inhibit PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis. The American Society for Pharmacology and Experimental Therapeutics